Literature DB >> 32584617

Treatment strategies for isolated systolic hypertension in elderly patients.

Fabio Angeli1,2, Paolo Verdecchia3, Sergio Masnaghetti2, Gaetano Vaudo4, Gianpaolo Reboldi4.   

Abstract

INTRODUCTION: Hypertension is a major and modifiable risk factor for cardiovascular disease. Its prevalence is rising as the result of population aging. Isolated systolic hypertension mostly occurs in older patients accounting for up to 80% of cases. AREAS COVERED: The authors systematically review published studies to appraise the scientific and clinical evidence supporting the role of blood pressure control in elderly patients with isolated systolic hypertension, and to assess the influence of different drug treatment regimens on outcomes. EXPERT OPINION: Antihypertensive treatment of isolated systolic hypertension significantly reduces the risk of morbidity and mortality in elderly patients. Thiazide diuretics and dihydropyridine calcium-channel blockers are the primary compounds used in randomized clinical trials. These drugs can be considered as first-line agents for the management of isolated systolic hypertension. Free or fixed combination therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and calcium-channel blockers or thiazide-like diuretics should also be considered, particularly when compelling indications such as coronary artery disease, chronic kidney disease, diabetes, and congestive heart failure coexist. There is also hot scientific debate on the optimal blood pressure target to be achieved in elderly patients with isolated systolic hypertension, but current recommendations are scarcely supported by evidence.

Entities:  

Keywords:  Elderly; blood pressure reduction; chronic disease; clinical trials; frailty; isolated systolic hypertension; therapy

Mesh:

Substances:

Year:  2020        PMID: 32584617     DOI: 10.1080/14656566.2020.1781092

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  1 in total

1.  Effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function and inflammatory factor levels in elderly patients with coronary heart disease.

Authors:  Hongyun Gao; Juanjuan Han; Guoping Li; Wenjing Zhang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.